The $100 million PROTECT-Cog study studies at-risk older adults without cognitive problems, not people who already have mild cognitive impairment. Mild cognitive impairment, or MCI, means clear memory or thinking changes that do not block daily life. PROTECT-Cog is a prevention trial, not a treatment for current MCI or dementia. That distinction shapes who can join and what families with MCI should do instead.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
What PROTECT-Cog aims to prevent
PROTECT-Cog tests coached lifestyle habits plus a metabolism drug such as a GLP-1 agonist. The goal is less cognitive decline, MCI, and dementia in at-risk older adults, according to the Alzheimer's Association in its launch announcement. The design builds on earlier prevention work including U.S.
POINTER, LatAm FINGERS, and FINGER. It is described as combined-therapy prevention research, not care for existing dementia. Participants receive either intensive coached lifestyle support or a lighter structured lifestyle program. Only a subset also receives the metabolism or immune-modulating drug while researchers track MCI onset, frailty, and quality of life.
Who was studied
The studied group is older adults at higher risk who remain cognitively unimpaired. Prevention starts before symptoms begin, so normal test scores at entry matter. Its predecessor, U.S.
POINTER, enrolled 2,111 cognitively unimpaired adults with an average age of 68.2, according to NeurologyLive in its trial summary. Participants had a sedentary lifestyle, suboptimal diet, and added cardiometabolic risk. PROTECT-Cog carries that approach forward for at-risk older adults. One group gets intensive coaching and the other gets structured but lighter lifestyle guidance.
Who was not studied
People already living with MCI or dementia were not the studied group. U.S. POINTER required strong entry scores, including a Telephone Interview for Cognitive Status score of at least 32 and a Clinical Dementia Rating of 0.5 or lower, according to the Alzheimer's Association design paper in the published design paper.
Those cutoffs screen out significant impairment. A person who already meets MCI criteria would fall outside that prevention population. The same line applies to PROTECT-Cog. It watches for new MCI during follow-up rather than treating MCI present at the start.
What can people with MCI do now
Do not wait for PROTECT-Cog as treatment. People with an MCI diagnosis need current care and trials made for MCI.
Useful next steps include: Bring a family member to visits and keep a short list of changes, drugs, and questions. Ask the care team which local trials accept people with MCI.
- Ask the diagnosing clinic for causes, follow-up testing, and a care plan
- Review heart, sleep, mood, hearing, vision, and medication factors
- Seek support for daily routines, safety, driving, work, and planning
- Search for trials that explicitly enroll participants with MCI
You Might Also Like
- LatAm-FINGERS Lifestyle Coaching Findings Across 11 Countries in 2026: What the Evidence Supports and Does Not Promise for People With Mild Cognitive Impairment
- p-tau217 Findings a Decade Before Alzheimer’s Symptoms in 2026: How People With Mild Cognitive Impairment Can Avoid Overreading the Headline
- AAIC 2026 PROTECT-Cog Lifestyle and GLP-1 Trial: How People With Mild Cognitive Impairment Can Avoid Overreading the Headline
